Lenacapavir is the first approved antiretroviral that targets the HIV-1 capsid protein rather than a viral enzyme. That distinction matters clinically: because it acts on a structural target, its resistance profile does not overlap with the four classic antiretroviral classes. It is indicated, together with optimized background therapy, for heavily treatment-experienced adults with multidrug-resistant HIV-1.
The capsid is the conical protein shell that packages viral genetic material. Lenacapavir binds a pocket at the interface between capsid subunits and stabilizes the lattice through hydrophobic and electrostatic interactions. This stabilizing effect distorts the capsid so that newly formed virions are defective and far less infectious.
Lenacapavir acts at more than one stage. Early, it impedes the nuclear import of viral cDNA by disrupting the binding of host factors needed for entry into the nucleus, which limits how much proviral DNA integrates. Late, it accelerates capsid assembly into misshapen structures. Unlike most antiretrovirals, it does not directly block reverse transcription.
Because lenacapavir does not target integrase, reverse transcriptase, protease, or entry proteins, viruses resistant to those classes generally remain susceptible. Resistant capsid substitutions can still emerge, so it is used with other active agents rather than alone. Its long half-life supports an every-six-month subcutaneous schedule after an oral loading phase, easing adherence for complex regimens.
Lenacapavir does not replace standard regimens but extends options for people who have exhausted many classes. Its value is greatest when the optimized background regimen still contains active agents, because resistance emerges most readily in functional monotherapy. For programs managing complex cases, the long-acting schedule can also reduce the pill burden that undermines adherence. These attributes position it as a specialized tool within a broader antiretroviral strategy rather than a first-line default. Ongoing studies continue to explore its role in prevention as well, though current approved use remains the treatment of multidrug-resistant infection in combination with other therapy.
Q: What makes lenacapavir different from other HIV drugs? A: It is a capsid inhibitor acting on a structural viral protein, giving it a resistance profile that does not overlap the classic enzymatic drug classes.
Q: Is it used by itself? A: No. It is indicated only with other active antiretroviral agents, because monotherapy risks selecting for resistant capsid variants.
Q: Why is the dosing schedule so infrequent? A: The molecule has a long tissue half-life, allowing an initial oral load followed by subcutaneous injections every six months under supervision.
Lenacapavir is the first approved antiretroviral that targets the HIV-1 capsid protein rather than a viral enzyme. That distinction matters clinically: because it acts on a structural target, its resistance profile does not overlap with the four classic antiretroviral classes. It is indicated, together with optimized background therapy, for heavily treatment-experienced adults with multidrug-resistant HIV-1.
The capsid is the conical protein shell that packages viral genetic material. Lenacapavir binds a pocket at the interface between capsid subunits and stabilizes the lattice through hydrophobic and electrostatic interactions. This stabilizing effect distorts the capsid so that newly formed virions are defective and far less infectious.
Lenacapavir acts at more than one stage. Early, it impedes the nuclear import of viral cDNA by disrupting the binding of host factors needed for entry into the nucleus, which limits how much proviral DNA integrates. Late, it accelerates capsid assembly into misshapen structures. Unlike most antiretrovirals, it does not directly block reverse transcription.
Because lenacapavir does not target integrase, reverse transcriptase, protease, or entry proteins, viruses resistant to those classes generally remain susceptible. Resistant capsid substitutions can still emerge, so it is used with other active agents rather than alone. Its long half-life supports an every-six-month subcutaneous schedule after an oral loading phase, easing adherence for complex regimens.
Lenacapavir does not replace standard regimens but extends options for people who have exhausted many classes. Its value is greatest when the optimized background regimen still contains active agents, because resistance emerges most readily in functional monotherapy. For programs managing complex cases, the long-acting schedule can also reduce the pill burden that undermines adherence. These attributes position it as a specialized tool within a broader antiretroviral strategy rather than a first-line default. Ongoing studies continue to explore its role in prevention as well, though current approved use remains the treatment of multidrug-resistant infection in combination with other therapy.
Q: What makes lenacapavir different from other HIV drugs? A: It is a capsid inhibitor acting on a structural viral protein, giving it a resistance profile that does not overlap the classic enzymatic drug classes.
Q: Is it used by itself? A: No. It is indicated only with other active antiretroviral agents, because monotherapy risks selecting for resistant capsid variants.
Q: Why is the dosing schedule so infrequent? A: The molecule has a long tissue half-life, allowing an initial oral load followed by subcutaneous injections every six months under supervision.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
